SCHEMBL4346362

SCHEMBL4346362

Cc1ccccc1Nc1ccc(CN(C)CC(O)c2ccccc2)cn1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
CNR2 P34972 1/20 0.43
CDK4 P11802 1/20 0.41
CDK2 P24941 1/20 0.41
TAAR1 Q96RJ0 1/20 0.40
RAB9A P51151 1/20 0.39
AOC3 Q16853 1/20 0.38
LMNA P02545 3/20 0.37
ALDH1A1 P00352 2/20 0.37
MAPK1 P28482 1/20 0.37
KCNJ1 P48048 2/20 0.36
HDAC1 Q13547 1/20 0.35
POLB P06746 1/20 0.35
MAPK10 P53779 1/20 0.35
HTT P42858 1/20 0.35
GAA P10253 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4343366 0.89 KDM4E (0.48) KDM4EMEN1KMT2ASMN1; SMN2CNR2
SCHEMBL4347258 0.88 MEN1 (0.49) KDM4EMEN1KMT2ASMN1; SMN2CNR2
SCHEMBL4340550 0.88 MEN1 (0.45) KDM4EMEN1KMT2ASMN1; SMN2CNR2
SCHEMBL4346732 0.83 KDM4E (0.45) KDM4EMEN1KMT2ASMN1; SMN2CNR2
SCHEMBL4346610 0.82 KDM4E (0.55) KDM4EMEN1KMT2ASMN1; SMN2CNR2
SCHEMBL4346767 0.76 MEN1 (0.55) KDM4EMEN1KMT2ASMN1; SMN2CNR2
SCHEMBL4342586 0.72 MEN1 (0.51) KDM4EMEN1KMT2ASMN1; SMN2CNR2
SCHEMBL4348629 0.72 HTT (0.52) KDM4EMEN1KMT2ASMN1; SMN2CNR2
SCHEMBL13993320 0.72 KDM4E (0.70) KDM4EMEN1KMT2ASMN1; SMN2CNR2
SCHEMBL14274010 0.72 KDM4E (0.70) KDM4EMEN1KMT2ASMN1; SMN2CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275611-A1 Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-11-05 US claimed
EP-2007707-A1 COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR Boehringer Ingelheim International GmbH (DE) 2008-12-31 EP claimed
WO-2007118041-A1 COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-10-18 WO claimed
US-20090275611-A1 Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-11-05 US disclosed
US-20090275611-A1 Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-11-05 US disclosed
US-20090275611-A1 Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-11-05 US disclosed
EP-2007707-A1 COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR Boehringer Ingelheim International GmbH (DE) 2008-12-31 EP disclosed
WO-2007118041-A1 COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-10-18 WO disclosed
WO-2007118041-A1 COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275611-A1 Compounds Which Modulate The CB2 Receptor CNR1, CNR2, OPRL1 KDM4E 3287/4885MEN1 4775/4885KMT2A 2988/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.